Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Risk of a second cancer after early breast cancer is low, say new findings

2.

Study suggests exercise could reduce breast cancer recurrence

3.

Study recommends new grading system for invasive squamous cell carcinoma of the lung

4.

Distribution of fat could influence cancer risk, study suggests

5.

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot